drugset / Trial / NCT05142423
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is a multi-center, open label, phase Ib/II clinical study of AK109 and AK104 to evaluate the safety, tolerability, effectiveness, pharmacokinetic characteristics in advanced solid tumors .
Timeline
- Start
- 2021-11-03
- Primary completion
- 2027-04
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | — |
| Subject | pulocimab | Monoclonal antibody | 10 mg/kg | — |
| Subject | pulocimab | Monoclonal antibody | 15 mg/kg | — |
Indications
No indication recorded.